Homology medicines, inc. (FIXX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-35,331

-24,167

-29,627

-26,270

-23,852

-18,786

-14,148

-12,426

-10,217

-11,905

-6,527

-6,002

-5,554

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

1,907

1,719

1,691

1,642

1,266

563

268

237

221

200

189

163

130

Amortization of right-of-use assets

221

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

2,883

2,436

1,986

1,970

1,243

955

719

569

380

160

57

30

27

Amortization of premium on short-term investments

175

270

401

539

661

1,200

500

-234

123

-

-

-

-

Change in fair value associated with convertible preferred stock tranche liability

-

-

-

-

-

-

-

-

-

0

0

0

876

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-1,087

-218

1,434

438

-4,413

-1,375

2,248

2,402

1,728

1,195

-223

100

390

Accounts payable

4,841

-5,963

935

661

-85

4,954

-3,138

2,056

511

1,188

382

-201

350

Accrued expenses and other liabilities

-535

194

1,819

1,706

-1,404

1,211

1,476

1,119

-764

210

244

478

-69

Deferred revenue

-203

-190

-146

-141

-92

-406

-546

-475

-463

-

-

-

-

Deferred rent

-

323

307

261

-1,301

-3,128

-4,425

-1,341

-1,139

-63

19

-36

-105

Operating lease liabilities

-541

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-25,846

-26,333

-25,484

-21,670

-17,871

-8,079

-13,692

-9,747

-11,044

22,047

-5,448

-5,595

-4,524

Purchases of short-term investments

-

29,002

67,914

105,008

84,467

12,868

88,690

125,175

18,595

-

-

-

-

Maturities of short-term investments

117,030

12,700

56,500

72,625

114,600

39,000

48,260

34,950

26,270

-

-

-

-

Purchases of property and equipment

2,033

3,725

1,723

5,919

10,466

15,930

4,825

3,149

1,035

336

299

473

848

Net cash provided by investing activities

114,997

-20,027

-13,137

-38,302

19,667

10,202

-45,255

-93,374

6,640

-79,904

-299

-473

-848

Cash flows from financing activities:
Proceeds from issuance of common stock pursuant to employee stock purchase plan

537

0

433

0

396

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock from option exercises

135

66

209

55

21

42

-40

16

69

-

-

-

-

Payment of deferred offering costs

225

-

-

-

92

-

-

-

1,027

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

20,479

Net cash provided by financing activities

447

22,575

614

134,699

325

41

25

151,886

-958

11,662

83,087

0

20,479

Net change in cash, cash equivalents and restricted cash

89,598

-23,785

-38,007

74,727

2,121

2,164

-58,922

48,765

-5,362

-46,193

77,339

-6,068

15,106

Reclassification of liability for common stock vested

12

13

11

18

18

18

51

-10

16

204

0

0

20

Property and equipment additions included in accounts payable

405

-227

-444

-4,148

5,274

-344

9,241

203

27

29

-9

-67

214

Property and equipment additions included in accrued expenses and other liabilities

23

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on available for sale securities, net

-202

-

-

-

83

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

77

-

-

-147

174

-

-

-

2,046

-

-

-

-